|[February 04, 2013]
WAISMANN METHOD® Director Urges Physicians to Curb Hydrocodone Prescriptions
BEVERLY HILLS, Calif. --(Business Wire)--
Following recommendations from an advisory panel to the United States
Food and Drug Administration (FDA) proposing tighter restrictions on hydrocodone
drugs, for example Vicodin,
Norco and Lortab, Clare Waismann, registered addiction specialist and
administrative director for the WAISMANN METHOD® opiate treatment, is
urging doctors nationwide to practice restraint in prescribing these
medications due to their highly-addictive chemical nature.
"Although I applaud the FDA for considering tighter restrictions on
hydrocodone-combination drugs, medical professionals also need to take
greater ownership and responsibility for the rampant prescribing and
misuse of prescription painkillers in this country," said Waismann.
"It's unfortunately become common practice for some doctors to
overprescribe hydrocodone drugs and write prescriptions for minor pains,
like back aches or tooth pain. Hydrocodone is dangerously habit forming
and just as addictive as narcotics like morphine and Heroin. By
overprescribing prescription painkillers, physicians are putting thei
patients at risk for developing serious, and sometimes fatal, health
issues that could have otherwise been avoided."
The new restrictions would reclassify all hydrocodone-containing drugs
from schedule III to schedule II; one of the most restricted categories
for prescription medications, which currently includes drugs like
oxycodone and methadone. According to IMS Health, approximately 131
million prescriptions were written for hydrocodone in 2010, making it
the most broadly prescribed drug in the U.S. Data collected by WAISMANN
METHOD® revealed a similar trend, as the majority of patients surveyed
indicated they started with a hydrocodone-based prescription that
eventually led them to take a stronger drug, like oxycodone. In 2012,
WAISMANN METHOD® treated nearly the same number of patients for
addiction to Norco, a hydrocodone-combination drug, as it did for
Heroin, OxyContin or methadone patients. Furthermore, many patients said
they were given a prescription for a minor injury and subsequently
became addicted unintentionally.
"The fact that hydrocodone abuse and overdoses have reached epidemic
proportions should be a warning sign for those of us in the medical
community and our patients about just how dangerous these drugs are,"
added WAISMANN METHOD® medical director, Dr. Michael Lowenstein. "We
sometimes have the misconception that simply because something is
prescribed or commonly used, that it is safe. In the case of hydrocodone
drugs, with their potential for abuse, overdose, and even death, this
couldn't be further from the truth."
For more information about WAISMANN METHOD® treatment please visit
opiates.com. For interviews contact Nicolette Surh at 877-975-3423 or
send an email to Nicolette(at)rkpr(dot)net.
About WAISMANN METHOD® Treatment
WAISMANN METHOD® opiate treatment is a safe and proven protocol for
opiate dependency that utilizes the most advanced medical and
psychological techniques available. Together Michael H. Lowenstein M.D.,
Clifford Bernstein M.D. and Clare Waismann, Registered Addiction
Specialist (RAS) created a treatment protocol based on a foundation of
safety, success and respect. Our detoxification and aftercare programs
are customized to each patient's individual needs and dependency
history, combining the most advanced medical treatment with personalized
assessment and aftercare. From rapid opiate detoxification under
sedation, to medically assisted detoxification and other forms of
treatment at Domus Retreat, our doctors, therapists and staff work with
patients to create personalized treatment and aftercare plans that
ensure a healthy and effective transition to life without opiates.
WAISMANN METHOD® patients achieve an extraordinarily high success rate
because the treatment doesn't take a cookie cutter approach to
addressing opiate dependency. We always put treatment and care over
blame and punishment. For more information, please visit opiates.com.
[ Back To Technology News's Homepage ]